ALLMedicine™ Waldenstrom Macroglobulinemia Center
Research & Reviews 110 results
Blood Treon SPP, Meid KE et. al.
Jul 21st, 2021 - MYD88 and CXCR4 mutations are common in Waldenström Macroglobulinemia (WM). Mutated CXCR4 (CXCR4Mut) impacts BTK-inhibitor response. We conducted a Phase I trial of the CXCR4-antagonist ulocuplumab with ibrutinib in this first-ever study to target...
Clinical and Experimental Medicine; Gavriatopoulou M, Terpos E et. al.
Jul 20th, 2021 - Vaccination against SARS-CoV-2 is considered as the most important preventive strategy against COVID-19, but its efficacy in patients with hematological malignancies is largely unknown. We investigated the development of neutralizing antibodies (N...
The International Journal of Lower Extremity Wounds; Nekooghadam SM, Bozorgmehr R et. al.
Jun 24th, 2021 - Waldenstrom macroglobulinemia (WM), a rare malignant disorder, occurs as a result of abnormal proliferation of lymphocytes that produce immunoglobulin M. In rare cases, WM complicates by type I cryoglobulinemia. Type I cryoglobulinemia usually pre...
https://doi.org/10.1007/s00277-021-04474-3 10.1182/blood-2016-01-643569 10.1182/blood-2008-08-174961 10.1038/nature07205 10.3389/fimmu.2014.00276 10.1038/bcj.2017.37 10.1182/blood-2016-04-711234 10.1111/bjh.14201 10.3390/vaccines4040038 10.1007/s13277-016-5124-9 10.1111/cas.13020 10.1309/AJCPUJGMVV6ZF4GG 10.1182/blood-2008-04-150854 10.1056/NEJMoa1708566 10.1182/bloodadvances.2018021113 10.1016/j.mad.2005.11.001 10.1016/j.clim.2007.12.002 10.1093/annonc/mdz032 10.7717/peerj.2487
Annals of Hematology; Cao X, Kong YL et. al.
Mar 2nd, 2021 - Waldenstrom macroglobulinemia (WM) is a rare type of non-Hodgkin lymphoma with great heterogeneity, and the data of peripheral blood T-lymphocyte subsets in WM are limited. This study aimed to investigate the clinical correlation and distribution ...
Clinical Lymphoma, Myeloma & Leukemia; Velier M, Priet S et. al.
Feb 10th, 2021 - Severe and Irreversible Pancytopenia Associated With SARS-CoV-2 Bone Marrow Infection in a Patient With Waldenstrom Macroglobulinemia.|2021|Velier M,Priet S,Appay R,Atieh T,Lepidi H,|
Clinicaltrials.gov 6 results
May 4th, 2020 - PRIMARY OBJECTIVES: I. To determine the maximum tolerated dose (MTD) of temsirolimus in combination with bortezomib, rituximab, dexamethasone in patients with relapsed Waldenstrom's macroglobulinemia and relapsed/refractory mantle cell, follicular...
Jul 10th, 2018 - Waldenstrom macroglobulinemia (WM) is an incurable B-cell lymphoproliferative disorder characterized by expansion of malignant B-lymphocytes and excessive production of monoclonal IgM. The survival and proliferation of the neoplastic WM cells is h...
Apr 8th, 2018 - The progression free survival (PFS) expected for lymphoplasmacytic/lymphoplasmocytoid lymphoma/Waldenstrom macroglobulinemia with the same characteristics indicated into the study and treated with standard Rituximab plus chemotherapy may be estima...
Mar 29th, 2018 - PRIMARY OBJECTIVES: I. To assess tumor response to R-CyBor-D in patients with relapsed follicular (Gr 1 or 2), mantle cell, marginal zone lymphomas, small lymphocytic lymphoma (SLL)/chronic lymphocytic leukemia (CLL) and lymphoplasmacytic (Waldens...
Oct 15th, 2017 - Participants will be asked to complete a medical survey which includes demographics, diagnosis, and treatment history, medical history, lab results and symptoms experienced. Participants will then receive instructions for the tissue banking proced...
News 10 results
Jan 26th, 2021 - Ibrutinib (Imbruvica) has "become for many clinicians the treatment of choice" for patients with relapsed or refractory Waldenstrom macroglobulinemia (WM). This class of agents (Bruton tyrosine kinase [BTK] inhibitors) represents a "paradigm shift...
Oct 9th, 2019 - Patients in the early stages of Waldenstrom macroglobulinemia (WM), a rare type of non-Hodgkin lymphoma, are usually followed with observation rather than offered treatment and are labeled "asymptomatic." But this label is inaccurate because many ...
Nov 29th, 2018 - The guidelines on the diagnosis, treatment, and follow-up of Waldenstrom macroglobulinemia were released on October 1, 2018, by the European Society for Medical Oncology (ESMO). Diagnosis Waldenstrom macroglobulinemia (WM) is diagnosed based on...
Mary Ellen Schneider
Oct 18th, 2018 - Discontinuing ibrutinib therapy because of disease progression was associated with worse survival, according to a real-world study of ibrutinib dosing in chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma patients. Courtesy Wikimedia Comm.
Mary Ellen Schneider
Jun 26th, 2018 - Ibrutinib in combination with rituximab as a treatment for Waldenström macroglobulinemia (WM) is under priority review by the Food and Drug Administration. Ibrutinib, a Bruton’s tyrosine kinase inhibitor, is already approved as a single agent for.